Photo from Earle Burgess/LinkedIn
Jan 31, 2024, 17:49
Earle Burgess: Initial results from a small pilot study in late mCRPC where there are limited to no effective treatment options available
Earle Burgess, Genitourinary Oncologist at Atrium Health Levine Cancer, shared on LinkedIn:
“Enfortumab vedotin is a blockbuster drug in bladder cancer.
Looks like it might have activity in prostate cancer as well.
Initial results from a small pilot study in late mCRPC where there are limited to no effective treatment options available.
Large unmet need in this setting, so this could be a big deal if confirmed.”
Read Further.
Source: Earle Burgess/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 12:18
Dec 21, 2024, 11:52
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25
Dec 21, 2024, 11:18